These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 10943907)

  • 41. Preclinical and clinical pharmacology of alcohol dependence.
    Tambour S; Quertemont E
    Fundam Clin Pharmacol; 2007 Feb; 21(1):9-28. PubMed ID: 17227441
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Pharmacological treatment of alcohol dependence. Acamprosate and naltrexone offer new approach].
    Berglund M; Balldin J; Bendtsen P; Borg S; Franck J; Gustafsson L; Halldin J; Månsson M; Nilsson LH; Stolt G; Willander A
    Lakartidningen; 1997 Jul; 94(30-31):2645-8. PubMed ID: 9273426
    [No Abstract]   [Full Text] [Related]  

  • 43. Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat.
    Spanagel R; Putzke J; Stefferl A; Schöbitz B; Zieglgänsberger W
    Eur J Pharmacol; 1996 Jun; 305(1-3):45-50. PubMed ID: 8813530
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.
    Snyder JL; Bowers TG
    Am J Drug Alcohol Abuse; 2008; 34(4):449-61. PubMed ID: 18584575
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of age at drinking onset on the alcohol deprivation effect and stress-induced drinking in female rats.
    Füllgrabe MW; Vengeliene V; Spanagel R
    Pharmacol Biochem Behav; 2007 Feb; 86(2):320-6. PubMed ID: 17098280
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate.
    Umhau JC; Schwandt ML; Usala J; Geyer C; Singley E; George DT; Heilig M
    Neuropsychopharmacology; 2011 May; 36(6):1178-86. PubMed ID: 21289601
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Potential neuroprotective effects of acamprosate.
    Koob GF; Mason BJ; De Witte P; Littleton J; Siggins GR
    Alcohol Clin Exp Res; 2002 Apr; 26(4):586-92. PubMed ID: 11981137
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of alcohol dependence: recent progress and reduction of consumption.
    Testino G; Leone S; Borro P
    Minerva Med; 2014 Dec; 105(6):447-66. PubMed ID: 25392958
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term alcohol self-administration with repeated alcohol deprivation phases: an animal model of alcoholism?
    Spanagel R; Hölter SM
    Alcohol Alcohol; 1999; 34(2):231-43. PubMed ID: 10344783
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Time course of acamprosate action on operant ethanol self-administration after ethanol deprivation.
    Hölter SM; Landgraf R; Zieglgänsberger W; Spanagel R
    Alcohol Clin Exp Res; 1997 Aug; 21(5):862-8. PubMed ID: 9267536
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study.
    Mann K; Kiefer F; Smolka M; Gann H; Wellek S; Heinz A;
    Alcohol Clin Exp Res; 2009 Apr; 33(4):674-83. PubMed ID: 19170666
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Acamprosate--new preclinical research aspects].
    Spanagel R; Mann K
    MMW Fortschr Med; 2003 Oct; 145 Suppl 3():61-4. PubMed ID: 15490768
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acamprosate for alcohol dependence?
    Drug Ther Bull; 1997 Sep; 35(9):70-2. PubMed ID: 9350085
    [No Abstract]   [Full Text] [Related]  

  • 54. Effect of naltrexone on human alcohol consumption.
    Swift RM
    J Clin Psychiatry; 1995; 56 Suppl 7():24-9. PubMed ID: 7673102
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acamprosate (Campral) for alcoholism.
    Conn Med; 2005 Apr; 69(4):227-8. PubMed ID: 15926637
    [No Abstract]   [Full Text] [Related]  

  • 56. The development of acamprosate as a treatment against alcohol relapse.
    Kufahl PR; Watterson LR; Olive MF
    Expert Opin Drug Discov; 2014 Nov; 9(11):1355-69. PubMed ID: 25258174
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.
    Morley KC; Teesson M; Reid SC; Sannibale C; Thomson C; Phung N; Weltman M; Bell JR; Richardson K; Haber PS
    Addiction; 2006 Oct; 101(10):1451-62. PubMed ID: 16968347
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders.
    Domi E; Barbier E; Augier E; Augier G; Gehlert D; Barchiesi R; Thorsell A; Holm L; Heilig M
    Neuropsychopharmacology; 2018 Aug; 43(9):1805-1812. PubMed ID: 29463912
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland.
    Buri C; Moggi F; Giovanoli A; Strik W
    Alcohol Alcohol; 2007; 42(4):333-9. PubMed ID: 17517820
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy.
    Feeney GF; Connor JP; Young RM; Tucker J; McPherson A
    Alcohol Alcohol; 2006; 41(3):321-7. PubMed ID: 16467406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.